HomeCompareMBII vs EQR

MBII vs EQR: Dividend Comparison 2026

MBII yields 250.60% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MBII wins by $467.83M in total portfolio value
10 years
MBII
MBII
● Live price
250.60%
Share price
$0.80
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$467.88M
Annual income
$262,117,387.00
Full MBII calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — MBII vs EQR

📍 MBII pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMBIIEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MBII + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MBII pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MBII
Annual income on $10K today (after 15% tax)
$21,300.59/yr
After 10yr DRIP, annual income (after tax)
$222,799,778.95/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, MBII beats the other by $222,795,124.68/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MBII + EQR for your $10,000?

MBII: 50%EQR: 50%
100% EQR50/50100% MBII
Portfolio after 10yr
$233.96M
Annual income
$131,061,431.30/yr
Blended yield
56.02%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

MBII
Analyst Ratings
5
Buy
3
Hold
Consensus: Buy
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MBII buys
0
EQR buys
0
No recent congressional trades found for MBII or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMBIIEQR
Forward yield250.60%5.87%
Annual dividend / share$2.00$3.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$467.88M$47.8K
Annual income after 10y$262,117,387.00$5,475.61
Total dividends collected$445.94M$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: MBII vs EQR ($10,000, DRIP)

YearMBII PortfolioMBII Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$35,760$25,059.52$11,380$679.82+$24.4KMBII
2$122,012$83,749.18$13,014$837.25+$109.0KMBII
3$397,612$267,058.97$14,961$1,036.20+$382.7KMBII
4$1,238,800$813,355.61$17,297$1,289.22+$1.22MMBII
5$3,693,827$2,368,311.37$20,121$1,613.15+$3.67MMBII
6$10,552,190$6,599,794.32$23,561$2,030.84+$10.53MMBII
7$28,911,115$17,620,272.02$27,783$2,573.54+$28.88MMBII
8$76,053,022$45,118,129.07$33,013$3,284.39+$76.02MMBII
9$192,299,052$110,922,318.76$39,547$4,223.51+$192.26MMBII
10$467,877,373$262,117,387.00$47,791$5,475.61+$467.83MMBII

MBII vs EQR: Complete Analysis 2026

MBIIStock

Marrone Bio Innovations, Inc. discovers, develops, and sells biological products for crop protection, crop health, and crop nutrition. Its products include Emergen, Foramin, Foramin ST, Optima, Takla, Pacesetter, Ympact, UBP, and UBP ST for increasing crop health, yield, and quality; Grandevo, a bioinsecticide that controls sucking and chewing insects through feeding; Haven, a plant health product to reduce sun stress and dehydration; Jet-Ag and Jet-Oxide peroxyacetic acid sanitizers that prevent, suppress, eliminate, and control algae, fungi, and bacterial diseases in agriculture and horticultural industries; and Majestene, a bionematicide to control soil-dwelling nematodes and certain soil borne insects. The company also offers Regalia and Stargus, which protects against fungal and bacterial diseases and enhances yields/quality; Venerate, a bioinsecticide that controls chewing and sucking insects and mites; and Zelto, a bionematicide that protects turf, including golf course fairways and greens, and promotes turf health by enhancing plant and root health. It provides its products directly through sales force, as well as through distributors and other commercial partners. The company formerly known as Marrone Organic Innovations, Inc. Marrone Bio Innovations, Inc. was incorporated in 2006 and is headquartered in Raleigh, North Carolina.

Full MBII Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this MBII vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MBII vs SCHDMBII vs JEPIMBII vs OMBII vs KOMBII vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.